Sélectionner une page

Breakthrought Solutions for Effective Therapies

Pictogramme tumeur


Anti-Cancer Solutions Targeting metastasis, failure and drug resistance

Pictogramme tumeur


Preventing cancers by Treating Obesity

Pictogramme tumeur

Viral Infection

Example : targeting adipose tissue HIV reservoir and  Covid19

About us


THERANOVIR is a young innovative Health-Tech company of Reserach and Devlopment of breakthrough therapies in 3 fields of closely related pathologies, Cancer, Obesity and associated metabolic diseases and Infectious Diseases by targeting a platform of signaling pathways regulated by the protein complex NRP-1/OBR, newly discovered by the CEO/CSO Dr. Zakia BELAID-SANDAL (PhD). THERANOVIR benefits from a global and exclusive license from INSERM transfert for the valuation of 2 families of granted patents in Europe, United States and Japan. THERANOVIR filed its own patent in January 2023.

THERANOVIR is developing an immunotherapeutic antibody NOV2 with a unique mode of action through its ability to enter into the nucleus of cancer cells and degrade their DNA in a target-dependent manner based on the NRP-1/OBR complex induced by leptin, without significant genotoxic effect on normal cells and with a very high probability of reactivation of the anti-tumor immune response.

Abstract 3293: Leptin induces breast cancer metastasis through a Neuropilin-1 (NRP-1)/OBR complex 
Zakia Belaid-Choucair(*) et  al .Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): 
AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3293. doi:10.1158/1538-7445.AM2014-3293. * Dr. ZAKIA BELAID-SANDAL (PhD)  ( Widow Choucair)

Theranovir rewards


THERANOVIR is a winner of :

  • Lab-SHAKER 2017 (Genopole),
  • Onco-Entrepreneurs 2018 (Cancer Campus, Villejuif),
  • HEC-Challenge+ 2019 (HEC Paris),
  • Ilab 2020 (Ministry of education and research),
  • Innov’up PIA 2021 (Ile-de-France region) competitions.




Co-founder-President / CEO/CSO

17 years of experience in leading and participating in oncology programs in France and abroad

3 co-invented patents

Elie MATTA (PhD)

Assistant Scientific Investigator

PhD in Oncology and Cancer Biology

Co-auteur of 3 publications in DNA Repair

They support us

THERANOVIR is looking for seed funds between Q2 and Q3 2023 allowing it to select the lead and enter the regulatory CMC phase



Head Office

Pépinière, Genopole entreprise
4 rue Pierre-Fontaine
91000 Evry-Courcouronnes

Laboratory R&D

Pavillon de Recherche 1 /Niv4/p401
Institut Gustave Roussy
Cancer Campus
114 Edouard Vaillant
94800 Villejuif




+ 33 1 42 11 60 43

This site is under construction. 

Come back in a few weeks to discover our expertise in details.